The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the longest-lasting and most accurate CGM approved in the United States. This ...

Credit: Dexcom. The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required. In ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...